Zobrazeno 1 - 10
of 57
pro vyhledávání: '"BIXUN LI"'
Autor:
YINGFANG LIANG1, BIXUN LI1, DANYAN OU1, GUOLIANG LI2 tvtvtv06-2019@qq.com, HAO ZENG3 1985008521@qq.com
Publikováno v:
Experimental & Therapeutic Medicine. Nov2023, Vol. 26 Issue 5, p1-4. 4p.
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundLipid metabolism and cancer-related inflammation are closely related to the progression and prognosis of colorectal cancer (CRC). Therefore, this study aims to establish novel nomograms based on the combined detection of preoperative blood
Externí odkaz:
https://doaj.org/article/149f250725304e109e1c0a2590429365
Publikováno v:
Frontiers in Pharmacology; 2024, p1-9, 9p
Autor:
Shuang Ren, Sisi Huang, Xinqing Ye, Luhuai Feng, Yang Lu, Chaonan Zhou, Juan Zhao, Tingting He, Junwei Wang, Bixun Li
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100377- (2021)
Non–small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient har
Externí odkaz:
https://doaj.org/article/0e6dc20c77064e6b87aea93bc87aa67f
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Dysregulation of microRNAs (miRNAs) and their targeted downstream genes is involved in the carcinogenesis and progression of colorectal cancer (CRC). miR-519b-3p has been reported to play an important role in several cancers. However, its function in
Externí odkaz:
https://doaj.org/article/58d17bc7fb6a4861aa6d2dd5bc92d220
Publikováno v:
American Journal of Therapeutics; Nov/Dec2023, Vol. 30 Issue 6, pe559-e561, 3p
Publikováno v:
American Journal of Therapeutics; Jul/Aug2023, Vol. 30 Issue 4, pe406-e408, 3p
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Pembrolizumab, a monoclonal antibody against programmed cell death-1 receptor, was licensed for advanced cancers. Although the use of pembrolizumab can enhance the effect of cancer treatment, it can increase immune-related adverse events. We describe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49c1b16aba310367aa4bc87602c5eaf
http://europepmc.org/articles/PMC7899305
http://europepmc.org/articles/PMC7899305
Publikováno v:
American Journal of Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655744a0078f9dc0e4d0822b29d01257
https://doi.org/10.1097/mjt.0000000000001493
https://doi.org/10.1097/mjt.0000000000001493
Publikováno v:
Anti-cancer agents in medicinal chemistry.
Objective: This article aims to establish a liquid biopsy system for gene detection of circulating tumor cells (CTC) in lung cancer, systematically analyze the significance of osimertinib resistance, and formulate an individualized diagnosis and trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::117565e074274255a9d177fb89fe3510
https://pubmed.ncbi.nlm.nih.gov/36345240
https://pubmed.ncbi.nlm.nih.gov/36345240